Browsing Tag
Inc.
380 posts
How the VALIANT Phase 3 data may strengthen EMPAVELI’s nephrology market position
Find out how Sobi’s VALIANT Phase 3 data may reshape EMPAVELI’s nephrology market position and what it means for rare kidney disease growth.
TBBK is back on retail radar, but can The Bancorp prove the story in Q1?
Is The Bancorp (NASDAQ: TBBK) worth watching before April 2026 earnings? Read the catalyst, valuation, risks, and retail investor roadmap now.
Replimune Group (NASDAQ: REPL) plans layoffs after FDA rejects Tudriqev again, forcing a biotech reset
Replimune plans layoffs after the FDA rejected Tudriqev again. Read what the setback means for REPL stock, cash runway, strategy, and rivals.
Why platinum-resistant ovarian cancer remains a high-stakes proving ground for CDH6-targeted ADCs
Can SIM0505 change NextCure’s oncology outlook? Read why platinum-resistant ovarian cancer is the key test case for 2026.
Meta keeps building its own AI empire, so why is it still writing giant checks to CoreWeave?
Meta adds $21bn to its CoreWeave AI cloud pact through 2032. Read what it means for AI inference, capex discipline, and infrastructure competition.
Agilysys (AGYS) deepens resort tech push with Deep Blue Hotel & Hot Springs live deployment
Agilysys expands at Deep Blue Hotel & Hot Springs in Australia. Read why this resort software rollout could matter for AGYS growth and investor sentiment.
Xponential Fitness (NYSE: XPOF) launches strategic review as board weighs sale, merger, or other shareholder value options
Xponential Fitness has launched a strategic review that could lead to a sale or merger. Read what it means for XPOF, franchisees, and investors.
Can Matinas BioPharma (MTNB) avoid delisting while trying to salvage MAT2203?
Matinas BioPharma faces NYSE American non-compliance over equity levels. Read what it means for MTNB, MAT2203, funding options, and delisting risk.
Why Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) just strengthened the Eylea HD case against Roche’s Vabysmo
Regeneron won FDA approval for every-20-week Eylea HD dosing in wet AMD and DME. Read what it means for Regeneron, rivals, and retinal drug markets.
Could non-invasive vagus nerve stimulation emerge as an adjunctive pathway for chronic mild traumatic brain injury and PTSD management?
Could electroCore’s non-invasive vagus nerve stimulation expand into chronic mild traumatic brain injury and PTSD care? Read the strategic implications.